Innovation

A Photoactivated Agent for Bonding Tissue Containing Type-I Collagen

University of Kansas
posted on 10/03/2005

A preliminary step in designing and synthesizing photoactivated compounds that could potentially be used as an alternative to sutures or staples in surgical wound closure of collagenous tissues.

Suggested Uses

The design and synthesis of a new light-activated cross-linking agent for Type-I collagen has been developed as a step in the long-term goal of surgically bonding collagenous tissues.

Innovation Details
 

Detailed Description

The primary means of surgical wound repair for torn or severed collagenous tissue (e.g. tendon) is suturing. Sutures can act as sites of inflammation and infection, thus hindering wound healing. Recent laser-based photothermal methods for surgical wound repair are intended to avoid suture-related problems, but can result in thermal tissue damage that delays the healing process.

The present invention is a preliminary step in designing and synthesizing photoactivated compounds that could potentially be used as an alternative to sutures or staples in surgical wound closure of collagenous tissues. The agent has been shown to bond ex vivo tendon and corneal samples as well as solid gelatin strips with UV exposures and may be ideal for bonding tissues high in type I collagen. Bond tensile strengths for the corneal and tendon samples are low compared to sutures.

Advantages:

� A light-activated collagen bonding agent replacing suture in wound closure

� Faster wound healing time

� Areas of the wound are firmly held together thus avoiding weakened corneal structure and possible future would failure

File Number: 99KUMC219 

Other Information: *State of Development* Available for exclusive and non-exclusive license *Testing* Extending and testing compounds


IP Protection


License Online

This innovation currently is not available for online licensing. Please contact Jim Baxendale at University of Kansas for more information.

request more info
People

Case Manager:

Icon_avatar Jim Baxendale

Innovations (48)

Followed By

Follow this innovation



No one is following this innovation.

Organization
Profile
Related Tags

Find more innovations


February 11, 2009

3,941 members 11,891 innovations 107 organizations

Browse

Dr. Jörg Knäblein – Technology Scouting, Bayer Schering Pharma AG

"Through the iBridge Network, I was able to find a mouse model I was looking for. The collaboration available through the iBridge Network is crucial in driving innovation and I'll continue using it as a valued resource."  read more...